Overview of Patrys Limited's Preclinical Data Announcement

Patrys Limited (ASX: $PAB) has announced positive preclinical data for its deoxymabs, PAT-DX1 and PAT-DX3, in animal models of the autoimmune disease ANCA vasculitis. The data, presented by Dr Kim O'Sullivan from Monash University at the 21st International Vasculitis Workshop in Barcelona, demonstrated the ability of PAT-DX1 and PAT-DX3 to inhibit the formation of neutrophil extracellular traps (NETs) and reduce inflammation and kidney injury in the animal model of ANCA vasculitis without suppressing the immune system.

Executive Commentary on Preclinical Data

We are pleased to present these important discoveries at the leading global meeting on vasculitis. We are particularly excited by the discovery that both PAT-DX1 and PAT-DX3 are able to reduce symptoms of inflammation without negatively impacting the immune system as this is one of the major side-effects of existing therapies for vasculitis. We are very excited by the results from Dr O'Sullivan's studies which suggest that there may be opportunities to develop deoxymabs as a therapeutic for ANCA vasculitis, and potentially for other related autoimmune diseases. It is particularly exciting to see the potential opportunities to develop or partner our deoxymab technology expand while our GMP manufacturing of PAT-DX1 is underway and nearing completion.

Summary of Patrys Limited's Preclinical Data Announcement

Patrys Limited (ASX: $PAB) presented positive preclinical data for its deoxymabs, PAT-DX1 and PAT-DX3, in animal models of ANCA vasculitis. The data showed that both deoxymabs were able to inhibit the formation of NETs, reduce inflammation, and kidney injury in the animal model without suppressing the immune system. This suggests potential opportunities to develop deoxymabs as a therapeutic for ANCA vasculitis and other related autoimmune diseases. The company is optimistic about the expanding opportunities to develop or partner their deoxymab technology while their GMP manufacturing of PAT-DX1 is underway and nearing completion.